NEW
YORK, May 17, 2024 /PRNewswire/ -- The
global pharmaceutical market in Denmark size is estimated to grow by
USD 852.1 mn from 2024-2028,
according to Technavio. The market is estimated to grow at a CAGR
of 3.63% during the forecast period.
For more insights on the forecast market size and
historic data (2018 - 2022) - Download Free sample
report in minutes
Forecast
period
|
2024-2028
|
Base Year
|
2023
|
Historic
Data
|
2018 - 2022
|
Segment
Covered
|
Class Type
(Musculoskeletal system, Nervous system, Respiratory system, and
Others), Distribution Channel (Offline and Online), Type
(Prescription drugs and OTC drugs), and Geography
(Europe)
|
Region
Covered
|
Denmark
|
Key companies
profiled
|
AbbVie Inc., ALK Abello
AS, Amgen Inc., AstraZeneca PLC, Baxter International Inc.,
Bayer AG, Biogen Inc., DANCANN PHARMA A S, Eli Lilly and Co., F.
Hoffmann La Roche Ltd., Ferring BV, FUJIFILM Corp., Genmab AS, H
Lundbeck AS, LEO Pharma AS, Novo Nordisk AS, ORIFARM GROUP A S,
ResoTher Pharma, Takeda Pharmaceutical Co. Ltd., and Zealand Pharma
A S
|
Key Market Trends Fueling Growth
In Denmark, the pharmaceutical
market is witnessing significant advancements in personalized
medicine, driven by progress in genomics, molecular diagnostics,
and bioinformatics. The Danish healthcare system integrates genomic
information into clinical decision-making processes, backed by
robust infrastructure, collaborative research initiatives, and a
patient-centric approach. This shift focuses on chronic diseases
such as diabetes, cancer, and allergies, with trials like the
SUSTAIN FORTE ongoing. Scandinavian universities, university
hospitals, and science parks contribute to research and development
in areas like respiration, urology, muscles, joints, bones,
hormones, sense organs, and dermatology. The Danish market includes
prescription drugs, public health insurance, and export commodities
like PDE4 inhibitors and cancer medicines. Tax rates and
prescription drugs are subjects of ongoing discussions in the
Danish political landscape.
Market Challenges
- The pharmaceutical market in Denmark navigates the complex task of
providing access to advanced therapies while managing healthcare
costs within a centralized system. The Danish Medicines Agency
(DKMA) regulates pricing and reimbursement, prioritizing
cost-effectiveness and sustainability. However, stringent
regulations, including reference pricing, can create challenges for
pharmaceutical companies, particularly for innovative or niche
medications in areas such as immune system, infection, respiration,
urology, muscles, joints, bones, hormones, sense organs,
dermatology, and cancer. Denmark's
focus on public health insurance and chronic disease management, as
seen in the SUSTAIN FORTE trial, further influences the market
landscape. Universities, university hospitals, and science parks
contribute to scientific advancements and exports in this sector.
Key commodities include PDE4 inhibitors and tax rates for
prescription drugs (Rx).
Research report provides comprehensive data on
impact of trend, driver and challenges - Buy
Report
Segment Overview
This pharmaceutical market in Denmark report extensively covers market
segmentation by
- Class Type
- 1.1 Musculoskeletal system
- 1.2 Nervous system
- 1.3 Respiratory system
- 1.4 Others
- Distribution Channel
- Type
- 3.1 Prescription drugs
- 3.2 OTC drugs
- Geography
1.1 Musculoskeletal system- In the Danish
pharmaceutical market, drugs targeting the musculoskeletal system,
including those addressing immune system disorders, infections,
respiration, urology, muscles, joints, and bones, hold significant
importance due to an aging population and increasing prevalence of
chronic diseases such as diabetes, cancer, and allergies. The
elderly demographic, which is projected to account for
approximately 25% of Denmark's
population of 6.3 million in 2040, requires pharmaceutical
interventions to manage age-related conditions like osteoarthritis,
osteoporosis, and rheumatoid arthritis. Furthermore, sedentary
lifestyles and desk-bound work contribute to musculoskeletal
issues, driving demand for drugs. The Danish market also exports
various pharmaceutical commodities, including PDE4 inhibitors and
cancer medicines, which are subject to specific tax rates. The
public health insurance system covers prescription drugs (Rx), and
universities, university hospitals, and science parks in
Scandinavia contribute to the advancement of research and
development in this field. According to Globocan 2020, chronic
diseases account for a substantial portion of the disease burden,
making the development of effective treatments a priority. Notable
trials, such as the SUSTAIN FORTE trial, focus on addressing
musculoskeletal disorders and hormonal imbalances.
For more information on market segmentation with
geographical analysis including forecast (2024-2028) and historic
data (2018 - 2022) - Download a Sample Report
Research Analysis
ai_research_analysis
Market Research Overview
The Pharmaceutical Market in Denmark is a significant sector, characterized
by its focus on research and development (R&D), innovation, and
high-quality standards. The market is driven by a large and aging
population, increasing prevalence of chronic diseases, and a strong
focus on preventive healthcare. The Danish government plays a
crucial role in the market through its universal healthcare system,
which ensures affordable access to medicines for its citizens. The
market is also influenced by international trends, such as the
shift towards personalized medicine and digital health solutions.
The Danish regulatory environment is known for its stringent
regulations, ensuring the safety and efficacy of medicines. The
market is expected to grow in the coming years, driven by these
factors and the ongoing development of new treatments and
technologies.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Class Type
-
- Musculoskeletal System
- Nervous System
- Respiratory System
- Others
- Distribution Channel
-
- Type
-
- Prescription Drugs
- OTC Drugs
- Geography
-
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/denmark-pharmaceutical-market-size-is-set-to-grow-by-usd-852-1-mn-from-2024-2028--high-investment-in-pharmaceutical-industry-to-boost-the-market-growth-technavio-302148610.html
SOURCE Technavio